CAR-T Therapy in Treating Solid Tumor: Application and Limitations
DOI:
https://doi.org/10.54097/3e12s589Keywords:
CAR-T therapy, lung cancer, colon cancer, ovarian cancer, solid tumor.Abstract
CAR-T therapy has emerged as a revolutionary approach in the battle against cancer. By leveraging the body's own immune system, this technique harnesses the power of T cells, which are genetically engineered to recognize specific antigens found on cancer cells. The procedure involves isolating lymphocytes from patients, followed by laboratory-based genetic modifications to infuse them with distinct CAR genes. Once these enhanced CAR-T cells are reintroduced into the patient, they actively target and neutralize cancer cells. However, the journey of CAR-T therapy is not without challenges. The selection of the right antigen is paramount, as an incorrect choice can lead to unintended consequences. Moreover, the application of this therapy in solid tumors presents its own set of complexities. This review aims to shed light on the clinical potential of CAR-T therapy, the obstacles faced in the realm of solid tumor treatment, and the ongoing research endeavors to refine and improve this promising therapeutic strategy.
Downloads
References
Novartis China. Novartis China. https://www.novartis.com.cn/.
Bristol Myers Squibb - Global Biopharmaceutical Company. www.bms.com. https://www.bms.com.
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL). www.kitepharma.com. https://www.kitepharma.com/news/press-releases/2022/9/kites-car-t-cell-therapy-tecartus-granted-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-acute-lymphoblastic-leukemia.
Cilta-cel Induces Strong Response in Chinese Patients with Relapsed/Refractory Multiple Myeloma. OncLive. 2022-10-28/2023-08-01. https://www.onclive.com/view/cilta-cel-induces-strong-response-in-chinese-patients-with-relapsed-refractory-multiple-myeloma.
Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO), Chinese Society of Hematology, Chinese Medical Doctor Association for Hematologists. Leukemia-lymphoma, 2022, 31(01): 1-10.
Flemming A. Cytotoxic CD4+ CAR T cells implicated in long-term leukaemia remission. Nature Reviews Immunology, 2022, 22(3): 146.
van Loo G, Bertrand M J M. Death by TNF: a road to inflammation. Nature Reviews Immunology, 2022, 23: 289-303.
Boulch M, Cazaux M, Loe-Mie Y, etc. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Science Immunology, 2021, 6(57): eabd4344.
Li N, Fu H, Hewitt S M, etc. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proceedings of the National Academy of Sciences, 2017, 114(32): E6623-E6631.
Xu J, Meng Q, Sun H, etc. HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. Cell Death & Disease, 2021, 12(12): 1109.
Poster Presentation on MCY-M11 at ASCO 2020 | MaxCyte Inc. MaxCyte Inc. https://investors.maxcyte.com/news-releases/news-release-details/poster-presentation-mcy-m11-asco-2020#:~:text=MCY-M11%20is%20a%20wholly-owned%2C%20non-viral%2C%20mRNA-based%20cell%20therapy.
Ovarian cancer biomarkers | Abcam Chinese website. www.abcam.cn. https://www.abcam.cn/content/ovarian-cancer-biomarkers-zh.
Tormoen G W, Crittenden M R, Gough M J. Role of the immunosuppressive microenvironment in immunotherapy. Advances in Radiation Oncology, 2018, 3(4): 520–526.
Titov A, Petukhov A, Staliarova A, etc. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death & Disease, 2018, 9(9): 897.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
